PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancerXianping Xu, Zhibin Luo, Qiang Gong et al.|Cancer Chemotherapy and Pharmacology|2024Cited by 7